IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-04-23 (fiercebiotech.com)
Ken Park, MD |
Ken has spent two decades in healthcare, focusing on innovative businesses and solutions for the life sciences industry. He advises clients on R&D strategy and leads Fortrea's productivity initiatives. At McKinsey & Co., he pioneered Real World Evidence in Life Sciences and co-led big data applications in healthcare. As VP at Elevance, he managed Carelon's operations and launched CalINDEX, a Health Information Exchange. At IQVIA, he built new business lines in data, R&D services, and genomics. |
Read more
2025-04-11 (hrtoday.in)
Regan Wyatt Appointed as Associate Director, Talent Acquisition at IQVIA - Global HR News & Updates
Regan Wyatt has been promoted to Associate Director, Talent Acquisition at IQVIA. She brings over two decades of recruiting leadership in life sciences and clinical staffing.
Read more
2025-03-31 (clinicalleader.com)
IQVIA eCOA Sculptor Portal Real-Time Data Tracking And Compliance Monitoring
Unlock real-time data tracking, customizable reporting, and proactive compliance monitoring with the IQVIA eCOA Sculptor Portal to enhance clinical...
Read more
2024-12-23 (businesswire.com)
Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute
Despite a drop in venture funding for digital health companies over the last two-and-a-half years, digital health products and solutions are expanding in sco...
Read more
2024-03-10 (kommersant.ru)
The fight against obesity is gaining momentum -
Sales of analogues of the Ovorpik (Semaglutid) in Russia in 2024 increased by more than three times. The popularity of the drug is explained by the massive problem of obesity - according to various estimates, in Russia up to 40% of the population suffers from this disease. Experts predict that the organic growth of sales will soon slow down in connection with the saturation of the market. But manufacturers do not stand still: they are already developing new, more advanced means to reduce weight and promote therapy as lifelong.
Read more
2021-11-02 (appliedclinicaltrialsonline.com)
Making Every Connection Count- IQVIA Connected Devices powers clinical trials with better data
Tuesday, November 2, 2021 at 11am EDT Get treatments to patients faster and deliver a better experience for both patients and clinical trial sites. Join IQVIA leaders Jeff Noll and Sara Pawley and learn how IQVIA matches the right connected device for each study protocol to enhance data quality, speed data collection, and accelerate trial outcomes.
Read more